Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Apr 01 04:00PM ET
8.00
Dollar change
-0.03
Percentage change
-0.37
%
Index- P/E- EPS (ttm)-11.75 Insider Own54.27% Shs Outstand18.70M Perf Week-9.30%
Market Cap133.90M Forward P/E- EPS next Y- Insider Trans-0.01% Shs Float18.70M Perf Month-20.12%
Income-58.77M PEG- EPS next Q- Inst Own6.17% Short Float0.30% Perf Quarter-23.89%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio2.23 Perf Half Y-56.47%
Book/sh22.48 P/B0.36 EPS next Y- ROA-38.00% Short Interest0.06M Perf Year-53.92%
Cash/sh7.07 P/C1.13 EPS next 5Y- ROE-45.37% 52W Range7.75 - 24.15 Perf YTD-17.18%
Dividend Est.- P/FCF- EPS past 5Y-6.86% ROI-51.87% 52W High-66.87% Beta0.67
Dividend TTM- Quick Ratio22.63 Sales past 5Y-20.00% Gross Margin- 52W Low3.23% ATR (14)1.14
Dividend Ex-Date- Current Ratio22.63 EPS Y/Y TTM72.12% Oper. Margin- RSI (14)35.76 Volatility13.30% 12.06%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom4.00 Target Price20.70
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q69.80% Payout- Rel Volume0.46 Prev Close8.03
Sales Surprise- EPS Surprise-66.26% Sales Q/Q- Earnings- Avg Volume25.54K Price8.00
SMA20-16.67% SMA50-17.81% SMA200-44.32% Trades Volume11,712 Change-0.37%
Mar-18-25 04:21PM
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagen Brett RChief Accounting OfficerMar 26 '25Sale8.979078,1351,925Mar 27 07:19 PM